Endogenous glucocorticoids inhibit myocardial inflammation induced by lipopolysaccharide: Involvement of regulation of histone deacetylation

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 1, 2012, Pages 33-41

  Zhang, Hai Ning ^a   He, Yan Hua ^a   Zhang, Gen Shui ^a   Luo, Miao Shan ^a   Huang, Yue ^a   Wu, Xiao Qian ^a   Liu, Shi Ming ^a   Luo, Jian Dong ^a   Chen, Min Sheng ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

endogenous GCs; HDAC; myocardial inflammation

Indexed keywords

CYTOKINE; GLUCOCORTICOID RECEPTOR; HISTONE DEACETYLASE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MIFEPRISTONE; TRICHOSTATIN A;

ADRENALECTOMY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEACETYLATION; ENZYME ACTIVITY; HEART FUNCTION; HISTONE ACETYLATION; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; HISTONE DEACETYLASES; HYDROCORTISONE; HYDROXAMIC ACIDS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MIFEPRISTONE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84863783588     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182567fef     Document Type: Article

References (25)

1. Nian M, Lee P, Khaper N, et al. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-1553.
2. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464-470.
3. Kan H, Finkel MS. Inflammatory mediators and reversible myocardial dysfunction. J Cell Physiol. 2003;195:1-11.
4. Panzer U, Steinmetz OM, Turner JE, et al. Resolution of renal inflammation: a new role for NF-kappaB1 (p50) in inflammatory kidney diseases. Am J Physiol Renal Physiol. 2009;297:F429-F439.
5. Melisi D, Niu J, Chang Z, et al. Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res. 2009;7:624-633.
6. Kastl SP, Speidl WS, Katsaros KM, et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood. 2009;114:2812-2818.
7. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci. 2009;1171:59-76.
8. Rahman I, Marwick J, Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol. 2004;68: 1255-1267.
9. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene. 2006;25: 6717-6730.
10. Ito K. Impact of post-translational modifications of proteins on the inflammatory process. Biochem Soc Trans. 2007;35(pt 2):281-283.
11. Adcock IM, Ito K, Barnes PJ. Glucocorticoids: effects on gene transcription. Proc Am Thorac Soc. 2004;1:247-254.
12. Rajendrasozhan S, Yang SR, Edirisinghe I, et al. Deacetylases and NFkappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal. 2008;10: 799-811.
13. Adcock IM, Ito K. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc. 2005;2:313-319.
14. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373:1905-1917.
15. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD. 2005;2:445-455.
16. Genth-Zotz S, von Haehling S, Blankenberg S. Immunoactivation in chronic heart failure. Inflammatory mediators [in German]. Z Kardiol. 2004;93(suppl 4):IV24-IV30.
17. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events resulted from the health ABC study. Circulation. 2003;108:2317-2322.
18. Yu Y, Wan Y, Huang C. The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target. Curr Cancer Drug Targets. 2009;9:566-571.
19. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967-1976.
20. Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol. 2006;291:L46-L57.
21. Moodie FM, Marwick JA, Anderson CS, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J. 2004;18:1897-1899.
22. Van Overveld FJ, Demkow U, Górecka D, et al. Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPD. J Physiol Pharmacol. 2006;57(suppl 4):273-282.
23. Ito K, Charron CE, Adcock IM. Impact of protein acetylation in inflammatory lung diseases. Pharmacol Ther. 2007;116:249-265.
24. Peterson CL. HDAC's at work: everyone doing their part. Mol Cell. 2002;9:921-922.
25. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 2006;203:7-13.